Less than a year after the global emergence of the coronavirus SARS-CoV-2, a novel
vaccine platform based on mRNA technology was introduced to the market. Globally, around …

Malaria accounts for an enormous burden of disease globally, with Plasmodium falciparum
accounting for the majority of malaria, and P. vivax being a second important cause …

Antibodies play major roles in immunity to malaria; however, a limited understanding of
mechanisms mediating protection is a major barrier to vaccine development. We have …

Malaria is a major disease of humans caused by protozoan parasites from the genus
Plasmodium. It has a complex life cycle; however, asexual parasite infection within the blood …

Clinical manifestations of Plasmodium falciparum infection are induced by the asexual
stages of the parasite that develop inside red blood cells (RBCs). Because splenic …

Background One of the criteria to objectively prioritize merozoite antigens for malaria
vaccine development is the demonstration that naturally acquired antibodies are associated …

Antibodies are essential molecules for diagnosis and treatment of diseases caused by
pathogens and their toxins. Antibodies were integrated in our medical repertoire against …

Individuals living in areas where malaria is endemic are repeatedly exposed to many
different malaria parasite antigens. Studies on naturally acquired antibody-mediated …

The relevance of the antibody-dependent cellular inhibition (ADCI) of Plasmodium
falciparum to clinical protection has been previously established by in vitro studies of …

Throughout history malaria has proved to be a significant threat to human health. Between
300 and 500 million clinical cases occur each year worldwide, approximately 2 million of …